2023
Does Preoperative MRI Reduce Positive Margins after Breast-Conserving Surgery?
Cairns A, Chagpar A, Dupont E, Levine E, Gass J, Chiba A, Ollila D, Howard-McNatt M. Does Preoperative MRI Reduce Positive Margins after Breast-Conserving Surgery? Annals Of Surgical Oncology 2023, 30: 6053-6058. PMID: 37505353, DOI: 10.1245/s10434-023-13884-8.Peer-Reviewed Original ResearchConceptsPreoperative magnetic resonance imagingMagnetic resonance imagingExtensive intraductal componentMargin statusPositive marginsTumor sizeTumor factorsMedian tumor sizeBreast conserving surgeryBreast cancer managementInvasive lobular histologyNeoadjuvant chemotherapyLobular histologyIntraductal componentMedian ageMulticenter trialPatient agePalpable tumorsPatient factorsShave marginsNegative marginsResultsA totalAssociated FactorsBreast cancerUS Centers
2014
Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients?
Chagpar A, Butler M, Killelea B, Horowitz N, Stavris K, Lannin D. Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients? Journal Of Clinical Oncology 2014, 32: 107-107. DOI: 10.1200/jco.2014.32.30_suppl.107.Peer-Reviewed Original ResearchMargin statusIntraoperative imagingFinal margin statusMedian tumor sizeBreast cancer patientsRe-excision ratesIntraoperative specimen radiographyCohort of interestIntraoperative marginsResidual tumorPartial mastectomyPositive marginsProspective studyTumor sizeCancer patientsInvasive cancerFurther excisionPathology resultsIntraoperative resectionPatientsDefinitive specimenSpecimen radiographyIntraoperative specimenSurgeons
2012
Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients?
Chagpar A, Neumeister V, Lannin D, Rimm D. Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients? Journal Of Clinical Oncology 2012, 30: 1121-1121. DOI: 10.1200/jco.2012.30.15_suppl.1121.Peer-Reviewed Original ResearchBreast cancer patientsLN statusCancer patientsLymphovascular invasionTumor sizeTumor markersPositive LNsPoor prognosisMedian numberPrimary tumor markersMedian patient ageMedian tumor sizeLymph node positivityLN-positive patientsLymph node statusOnly factorCancer initiating cellsCancer-initiating cellsLevels of CD44Axillary surgeryLN positivityNode positivityPatient agePositive patientsClinicopathologic data
2011
P1-01-15: Do Serum Cytokines Predict Breast Cancer Behavior?
Lush E, Dedert E, Daup M, Dhabhar F, Spiegel D, Tillie J, McMasters K, Sephton S, Chagpar A. P1-01-15: Do Serum Cytokines Predict Breast Cancer Behavior? Cancer Research 2011, 71: p1-01-15-p1-01-15. DOI: 10.1158/0008-5472.sabcs11-p1-01-15.Peer-Reviewed Original ResearchSerum cytokine levelsHormone receptor statusLymph node statusCytokine levelsReceptor statusTumor sizeBreast cancer behaviorSerum cytokinesNode statusCancer behaviorIFN-gamma serum levelsMedian patient ageMedian tumor sizeSerum IFN-gammaSerum inflammatory cytokinesProgesterone receptor statusRole of inflammationFinal pathologic resultsPresence of metastasesBreast cancer patientsBreast cancer developmentVariety of cytokinesCohort of interestLymphovascular invasionPatient age
2009
Use Pre- and Intra-Operative Data To Predict Probability of Positive Non-Sentinel Lymph Nodes.
Chagpar A, Blumencranz P, Whitworth P, Deck K, Rosenberg A, Simmons R, Reintgen D, Beitsch P, Julian T, Saha S, Mamounas E, Giuliano A, Cook E, Wang S. Use Pre- and Intra-Operative Data To Predict Probability of Positive Non-Sentinel Lymph Nodes. Cancer Research 2009, 69: 302-302. DOI: 10.1158/0008-5472.sabcs-09-302.Peer-Reviewed Original ResearchAxillary node dissectionNon-SLN metastasisTumor sizeIntra-operative dataBLN AssayPositive SLNMedian numberLogistic regression modelsPositive non-sentinel lymph nodesSentinel lymph node-positive patientsCompletion axillary node dissectionFrozen sectionsLymph node-positive patientsNon-sentinel lymph nodesStepwise logistic regression modelFurther positive nodesNon-SLN statusMedian tumor sizeNode-positive patientsPositive rateTumor size dataSignificant predictorsCohort of interestNode dissectionPositive nodesUse of intraoperative breast cancer sentinel lymph node (SLN) assay to predict of ≥4 positive (+) lymph nodes (LN)
Chagpar A, Blumencranz P, Whitworth P, Deck K, Rosenberg A, Simmons R, Reintgen D, Beitsch P, Saha S, Julian T. Use of intraoperative breast cancer sentinel lymph node (SLN) assay to predict of ≥4 positive (+) lymph nodes (LN). Journal Of Clinical Oncology 2009, 27: 530-530. DOI: 10.1200/jco.2009.27.15_suppl.530.Peer-Reviewed Original ResearchSentinel lymph nodesLymph nodesFinal pathologyTumor sizeMedian cycle timeBreast cancer sentinel lymph nodesTotal lymph nodesMedian tumor sizePositive lymph nodesImmediate breast reconstructionHematoxylin-eosin stainingReceiver operator curveCohort of interestBLN AssayQuantitative RT-PCRSLN metastasisProspective studyBreast reconstructionReal-time RT-PCR analysisMedian numberClinical utilityRadiation therapyPatientsMultivariate analysisMammaglobinFactors influencing the decision to add chemotherapy to adjuvant hormonal therapy in women with hormone receptor-positive breast cancer.
Chagpar A, Lewis J, McMasters K, Edwards M. Factors influencing the decision to add chemotherapy to adjuvant hormonal therapy in women with hormone receptor-positive breast cancer. Cancer Research 2009, 69: 4105. DOI: 10.1158/0008-5472.sabcs-4105.Peer-Reviewed Original ResearchAddition of chemotherapyHormone receptor-positive breast cancerReceptor-positive breast cancerAbsolute survival benefitAdjuvant hormonal therapyOverall survival benefitHormonal therapySurvival benefitOverall survivalAdjuvant chemotherapyClinicopathologic factorsAbsolute benefitBreast cancerHormone receptor-positive patientsReceptor-positive patientsTamoxifen Adjuvant trialMedian patient ageMedian tumor sizeMajority of patientsYears of ageCohort of interestAdjuvant trialsLymphovascular invasionPatient agePositive disease